Literature DB >> 21976914

Eccrine hidrocystoma successfully treated with topical synthetic botulinum Peptide.

Vijay Gandhi1, Geetanjali Naik, Prashant Verma.   

Abstract

Entities:  

Year:  2011        PMID: 21976914      PMCID: PMC3183727          DOI: 10.4103/0974-2077.85048

Source DB:  PubMed          Journal:  J Cutan Aesthet Surg        ISSN: 0974-2077


× No keyword cloud information.
Sir, Eccrine hidrocystomas (EHs) are benign cystic lesions of eccrine ducts that are associated with a chronic course and seasonal variations. They are more frequent in females than in males.[1] Solitary EH can be treated easily by surgical excision; however, the treatment of multiple lesions is problematic. We report a case of multiple eccrine hydrocystomas over the face, which responded completely after 4 weeks of treatment with topical Botulinum Toxin (Boxtlak-BL) like preparation. A 60-year-old Indian lady presented with multiple papules over the cheeks since last 5–6 years, which were persistent and aggravated in summer and on exposure to heat. On local examination, there were shiny, translucent papules of 1–3 mm in diameter on the centrofacial area. On puncturing with a disposable needle, clear watery fluid came out. A skin biopsy stained with haematoxylin and eosin showed dilated cystic spaces in upper dermis [Figure 1], which were unilocular and lined by flattened squamous epithelial cells in two layers. There were no myoepithelial cells in the cyst wall. There was no evidence of decapitation secretions in the lining cells.[2] Based on clinical features and histopathology, a diagnosis of multiple EHs was made. The patient was treated with topical Boxtlak-BL twice daily and there was almost complete clearance of lesions after 4 weeks of treatment [Figures 2 and 3].
Figure 1

Dilated unilocular cystic spaces lined by two layers of squamous epithelial cells without any evidence of decapitation secretions, (H and E, ×40)

Figure 2

Multiple eccrine hydrocystomas over the left cheek before treatment

Figure 3

After 4 weeks of topical treatment with Boxtlak-BL cream

Dilated unilocular cystic spaces lined by two layers of squamous epithelial cells without any evidence of decapitation secretions, (H and E, ×40) Multiple eccrine hydrocystomas over the left cheek before treatment After 4 weeks of topical treatment with Boxtlak-BL cream EH is a benign cystic condition of eccrine sweat ducts.[3] The aetiopathogenesis is still debatable. Electron microscopy has established that the cyst wall is composed of ductal cells. It is likely that obstruction of eccrine duct leads to retention of sweat causing flattening of the lining cells and cystic dilatation. Treatment of EH is recommended for cosmetic reasons. Different modalities have been proposed with variable results, which include puncture and drainage of the cyst that gives transient improvement with an early recurrence,[4] surgical excision,[4] microdermabrasion and electrodessication with high risk of scarring,[5] pulse dye laser,[6] topical atropine[7] and scopolamine.[8] Recently EH has been treated with botulinum toxin (injectable) with good results.[9] Botulinum toxin (Boxtlak-BL) is a potent neurotoxin that blocks cholinergic nerve terminals. It has been used in the treatment of blepharospasm, strabismus, torticollis, hemifacial spasm and other dystonias.[10] It has also been used in the treatment of hyperhidrosis[11] and facial wrinkles. Boxtlak-BL containing BoNT_L peptide significantly inhibits SNAP-25 (synaptosome-associated protein of 25 kd)[12] of SNARE complex thereby inhibiting the release of acetylcholine from vesicle within the cytoplasm of the motor nerve endings. The end result is chemodenervation of cholinergic nerves targeting the autonomic control of eccrine sweat glands. We propose topical Botulinum toxin like peptide as a painless, non-invasive, cost-effective and safe technique for the treatment of multiple EH with excellent results.
  9 in total

1.  Pulsed dye laser treatment of multiple eccrine hidrocystomas: a novel approach.

Authors:  E Tanzi; T S Alster
Journal:  Dermatol Surg       Date:  2001-10       Impact factor: 3.398

Review 2.  Pharmacology and immunology of botulinum toxin serotypes.

Authors:  K R Aoki
Journal:  J Neurol       Date:  2001-04       Impact factor: 4.849

Review 3.  Treatment of hyperhidrosis with botulinum toxin.

Authors:  Richard G Glogau
Journal:  Dermatol Clin       Date:  2004-04       Impact factor: 3.478

4.  Multiple eccrine hidrocystomas: report of two cases treated unsuccessfully with atropine ointment.

Authors:  Niti Khunger; Sharmila Mishra; R K Jain; Sunita Saxena
Journal:  Indian J Dermatol Venereol Leprol       Date:  2004 Nov-Dec       Impact factor: 2.545

5.  Multiple eccrine hidrocystomas: a nonsurgical treatment.

Authors:  H W Clever; W J Sahl
Journal:  Arch Dermatol       Date:  1991-03

6.  History of the cosmetic use of Botulinum A exotoxin.

Authors:  A Carruthers; J Carruthers
Journal:  Dermatol Surg       Date:  1998-11       Impact factor: 3.398

7.  Multiple eccrine hidrocystomas--from diagnosis to treatment: the role of dermatoscopy and botulinum toxin.

Authors:  Osvaldo Correia; Ana Filipa Duarte; Ana Margarida Barros; Natividade Rocha
Journal:  Dermatology       Date:  2009-05-07       Impact factor: 5.366

8.  Multiple eccrine hidrocystomas: a new therapeutic option with botulinum toxin.

Authors:  Guillermo Blugerman; Diego Schavelzon; Silvana D'Angelo
Journal:  Dermatol Surg       Date:  2003-05       Impact factor: 3.398

9.  Multiple hidrocystoma of the face: three cases.

Authors:  M C Fariña; E Piqué; M Olivares; P Escalonilla; L Martín; L Requena; J L Sarasa
Journal:  Clin Exp Dermatol       Date:  1995-07       Impact factor: 3.470

  9 in total
  2 in total

1.  Eccrine Hidrocystoma: A Report of Two Cases with Special Reference to Dermoscopic Features.

Authors:  Pradeep Kumar; Vijay Gandhi; Priti Kumari
Journal:  J Cutan Aesthet Surg       Date:  2021 Jan-Mar

Review 2.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.